



## MATERIAL SAFETY DATA SHEET

### SODIUM IODIDE I 131 ORAL THERAPEUTIC SOLUTION

#### SECTION 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

**Product Name:** Sodium Iodide I 131 Oral  
Therapeutic Solution  
**Synonyms:** I 131 solution  
**Manufacturer:** Mallinckrodt Inc.  
2703 Wagner Place  
Maryland Heights, MO 63043

**Revision Date:** January 1, 2003  
**Information Telephone Number:** (888) 744-1414  
**Emergency Telephone Number:** (314) 654-7860  
**CHEMTREC:** 1-800-424-9300  
**CANUTEC:** 613-996-6666

#### SECTION 2. COMPOSITION, INFORMATION ON INGREDIENTS

##### Chemical Ingredients:

| Component                 | CAS #     | Wt %     |
|---------------------------|-----------|----------|
| Sodium Iodide I 131       | 7790-26-3 | < 0.001% |
| EDTA Disodium Salt        | 139-33-3  | 0.2%     |
| Sodium Phosphate, Dibasic | 7558-79-4 | 0.5%     |
| Sodium Bisulfite          | 7631-90-5 | 0.1%     |
| Water                     | 7732-18-5 | 99.2%    |

#### SECTION 3. HAZARDS IDENTIFICATION

##### **EMERGENCY OVERVIEW**

CAUTION! RADIOACTIVE MATERIAL. Read Package Insert prior to use. Promptly remove any contamination from the skin, eyes, or clothing. Radioactive drugs must be handled by qualified personnel in conformity with regulations appropriate to the government agency authorized to license the use of this radionuclide. The vial containing the drug should be kept within its container or within heavier shielding. Avoid contact with the radioactive contents which would cause unnecessary exposure to radiation.

##### **POTENTIAL HEALTH EFFECTS**

###### **Inhalation:**

A very small fraction of the Sodium Iodide I 131 may break down and emit radioactive fumes containing I 131. Not expected to be a health hazard via inhalation.

###### **Ingestion:**

May cause asymptomatic physiological uptake by thyroid gland or other tissues.

###### **Skin Contact:**

Not expected to produce any acute adverse health effects.

###### **Eye Contact:**

No adverse effect expected, but may cause mechanical irritation.

###### **Chronic Exposure:**

The health risks associated with chronic radiation exposure (cancer, leukemia, genetic and teratogenic effects) are believed to involve levels of radiation exposure which are much higher than those permitted occupationally.

###### **Aggravation of Pre-existing Conditions:**

No information found.

SODIUM IODIDE I 131 ORAL THERAPEUTIC SOLUTION

## SODIUM IODIDE I 131 ORAL THERAPEUTIC SOLUTION

### SECTION 4. FIRST AID MEASURES

**Inhalation:**

Notify radiation safety personnel immediately. The amount of material inhaled should be assessed and documented.

**Ingestion:**

Notify radiation safety personnel immediately. The amount of I 131 in the thyroid gland should be assessed and documented. A thyroid blocking agent may be warranted and administered under the direction of a physician.

**Skin Exposure:**

If skin contact occurs, wash the affected area thoroughly with soap and water until no more radioactivity can be removed. Always blot dry. Do not abrade skin. Notify radiation safety personnel.

**Eye Exposure:**

If a splash occurs, wash eyes with water for at least 15 minutes or until no more radioactivity can be removed. Notify radiation safety personnel.

### SECTION 5. FIRE FIGHTING MEASURES

**Fire:** Not considered to be a fire hazard.

**Explosion:** Not considered to be an explosion hazard.

**Fire Extinguishing Media:** Use any means suitable for extinguishing surrounding fire.

**Special Instructions:** In the event of a fire, wear full protective clothing and NIOSH-approved self-contained breathing apparatus with full facepiece operated in the pressure demand or other positive pressure mode.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

If the product is received in a leaking condition or any loss or release of the radioactive contents occurs, notify your Radiation Safety Department and Mallinckrodt at (314) 654-7860. All cleanup operations should be performed according to the Standard Operating Procedures (SOPs) established for your facility and by the NRC or other applicable local, state or federal regulations.

### SECTION 7. HANDLING AND STORAGE

Store at 15°C to 30°C. Handling time should be kept to a minimum and appropriate shielding should be used. Handling devices such as syringe shields and tongs should be used. Storage and disposal of product should be controlled in a manner which is in compliance with the appropriate regulations of the federal or state government agency authorized to license the use of this radionuclide.

### SECTION 8. EXPOSURE CONTROLS, PERSONAL PROTECTION

**Airborne Exposure Limits:**

–NRC Occupational concentration limit is  $2 \times 10^{-8}$   $\mu\text{Ci/mL}$  of air.

**Engineering Controls:**

Properly sealed containers are not expected to require any special ventilation.

**Respiratory Protection:**

Not expected to require personal respirator usage.

**Skin Protection:**

Disposable plastic, latex, or rubber gloves; labcoat.

**Eye/Face Protection:**

Safety glasses.

**Precautions:**

No smoking, eating, or drinking should be allowed in any area where radioactive materials are handled or stored.

## SODIUM IODIDE I 131 ORAL THERAPEUTIC SOLUTION

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance:** Clear, colorless liquid in a 10 mL French-square, glass, screw-cap vial.

**Odor:** Odorless.

**Solubility:** Soluble in water.

**Boiling Point:** ca. 100°C (212°F).

**Melting Point:** ca. 0°C (32°F).

**Radioactivity:** From 3.5 to 150 mCi/vial on the calibration date and time.

**Concentration:** 3.5, 5.0 or 25.0 mCi/mL on the calibration date and time.

**Specific Activity:** 124 mCi/μg of Iodine on the calibration date and time.

**Half-Life:** ca. 8.04 days.

### SECTION 10. STABILITY AND REACTIVITY

**Stability:** Stable under ordinary conditions of use and storage. A very small fraction of the Sodium Iodide I 131 solution may break down and emit radioactive fumes containing I 131.

**Hazardous Decomposition Products:** May emit radioactive fumes containing I 131 when heated to decomposition.

**Hazardous Polymerization:** Will not occur.

**Incompatibilities:** No information found.

### SECTION 11. TOXICOLOGICAL INFORMATION

It is widely accepted by the scientific community that exposure to sufficient quantities of ionizing radiation can potentially cause harmful biological effects which include cancer, leukemia, and genetic and teratogenic effects. The uptake of I 131 can result in slight to total thyroid dysfunction. For detailed toxicological information on specific components, write to the address listed in Section 1 - Attn: Regulatory Compliance Department.

### SECTION 12. ECOLOGICAL INFORMATION

Because this product is intended for use by hospital or clinic patients, it is expected to be treated by standard wastewater treatment facilities with no adverse environmental impacts.

### SECTION 13. DISPOSAL CONSIDERATIONS

Sodium Iodide I 131 Oral Therapeutic Solution is Radioactive Waste until the activity has decayed to nondetectable levels. Radioactive waste must be handled in accordance with procedures established by your Radiation Safety Officer, NRC and other applicable regulations.

If medical waste is involved, such as blood, blood products, or sharps, the waste must be handled as a Biohazard and disposed of accordingly.

If not radioactive or a biohazard, waste Sodium Iodide I 131 Oral Therapeutic Solution is considered non-hazardous. Consult local, state and federal regulations for proper disposal.

### SECTION 14. TRANSPORT INFORMATION

**DOT (Department of Transportation):**

**Proper Shipping Name:** Radioactive Material, n.o.s.

**Hazard Class:** 7

**Identification Number:** UN2982

**RQ:** Shipments of 10 mCi or more per package must have "RQ" marked on the package exterior and on the shipping papers.

## SODIUM IODIDE I 131 ORAL THERAPEUTIC SOLUTION

### SECTION 15. REGULATORY INFORMATION

**CERCLA Reportable Quantities:**

I 131 = 0.01 Ci (3.7 E 8 Bq)

Releases to air, land or water of these hazardous substances which exceed the Reportable Quantity (RQ) must be reported to the National Response Center at 800-424-8802.

**SARA Title III**

302 Extremely Hazardous Substances: None

311/312 Hazard Categories: Chronic

313 Toxic substances subject to annual release reporting requirements: None.

**RCRA Hazardous Waste Status**

Non-hazardous (See Section 13 for additional details.)

**California Proposition 65 Warning**

This product contains a substance known to the State of California to cause cancer and reproductive toxicity.

**Australian Hazchem Code:** None allocated.

**Australian Poison Schedule:** None allocated.

**WHMIS:** This MSDS has been prepared according to the hazard criteria of the Controlled Products Regulations (CPR) and the MSDS contains all of the information required by the CPR.

### SECTION 16. OTHER INFORMATION

**MSDS Status:** Revised in accordance with ANSI Guideline Z400.1-1998

**NFPA Ratings:** Health: 1 Flammability: 0 Reactivity: 0

**Product Use:** Diagnostic imaging agent

**Revision Information:** Section 8 updated.

Mallinckrodt provides the information contained herein in good faith but makes no representation as to its comprehensiveness or accuracy. This document is intended only as a guide to the appropriate precautionary handling of the material by a properly trained person using this product. Individuals receiving the information must exercise their independent judgment in determining its appropriateness for a particular purpose. MALLINCKRODT MAKES NO REPRESENTATIONS OR WARRANTIES, EITHER

EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE INFORMATION SET FORTH HEREIN OR THE PRODUCT TO WHICH THE INFORMATION REFERS. ACCORDINGLY, MALLINCKRODT WILL NOT BE RESPONSIBLE FOR DAMAGES RESULTING FROM USE OF OR RELIANCE UPON THIS INFORMATION.

**tyco** / *Healthcare*

**MALLINCKRODT**

